Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “High-Risk, Non-Muscle Invasive Bladder Urothelial Carcinoma”

47 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 47 results

Testing effectiveness (Phase 2)Looking for participantsNCT07322263
What this trial is testing

Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC

Who this might be right for
Bladder CancerNon-Muscle Invasive Bladder Cancer (NMIBC)Urothelial Carcinoma+8 more
Michael A. O'Donnell 174
Not applicableEnded earlyNCT02202044
What this trial is testing

Sequential Intravesical Bacillus Calmette-Guérin and Electromotive Mitomycin-C After Transuretheral Resection

Who this might be right for
Bladder Carcinoma
University of Colorado, Denver 13
Large-scale testing (Phase 3)Active Not RecruitingNCT03091660
What this trial is testing

S1602: Different Strains of BCG With or Without Vaccine in High Grade Non- Muscle Invasive Bladder Cancer

Who this might be right for
Stage 0 Bladder Urothelial CarcinomaStage 0is Bladder Urothelial CarcinomaStage I Bladder Urothelial Carcinoma
SWOG Cancer Research Network 1,000
Large-scale testing (Phase 3)Not Yet RecruitingNCT07207824
What this trial is testing

DV+BCG in HER2-Expressing, BCG-Naïve High-Risk NMIBC

Who this might be right for
Bladder (Urothelial, Transitional Cell) CancerNMIBC
Fudan University 182
Testing effectiveness (Phase 2)UnknownNCT05495724
What this trial is testing

Disitamab Vedotin Combined With Tislelizumab for Her2 Overexpressing High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which is Not Completely Resectable

Who this might be right for
Her2 Overexpressing High-Risk Non-Muscle Invasive Bladder Urothelial Carcinoma
Tianjin Medical University Second Hospital 176
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07100184
What this trial is testing

RC48 in Combination With Radiotherapy for HER2-Expressing NMIBC Patients

Who this might be right for
HER2-expressing High-risk or Very High-risk NMIBC Without Visible Foci of Disease After TURBT
Peking University First Hospital 30
Testing effectiveness (Phase 2)Study completedNCT02015104
What this trial is testing

Study of Bacillus Calmette-Guerin (BCG) Combined With PANVAC Versus BCG Alone in Adults With High Grade Non-Muscle Invasive Bladder Cancer Who Failed At Least 1 Course of BCG

Who this might be right for
Bladder Cancer
National Cancer Institute (NCI) 32
Large-scale testing (Phase 3)Looking for participantsNCT06696794
What this trial is testing

Investigating the Efficacy and Safety of Neoadjuvant Intravesical Instillation of Mitomycin C in Treating High-risk NMIBC Patients

Who this might be right for
Non-Muscle-Invasive Bladder Cancer (NMIBC)
Shaogang Wang 180
Large-scale testing (Phase 3)Not Yet RecruitingNCT07480356
What this trial is testing

Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-grade Non-muscle Invasive Bladder Cancer

Who this might be right for
Bladder (Urothelial, Transitional Cell) CancerNon-Muscle Invasive Bladder CarcinomaNon-muscle Invasive Bladder Cancer With Carcinoma in Situ
Protara Therapeutics 284
Testing effectiveness (Phase 2)Looking for participantsNCT06770582
What this trial is testing

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial

Who this might be right for
Non-Muscle Invasive Bladder Urothelial CarcinomaRecurrent Non-Muscle Invasive Bladder Urothelial CarcinomaStage I Bladder Cancer AJCC v8
National Cancer Institute (NCI) 160
Post-approval studies (Phase 4)Active Not RecruitingNCT04701151
What this trial is testing

NORTH-REG Dwell-Time Study

Who this might be right for
Side Effect of Drug
Jørgen Bjerggaard Jensen 314
Large-scale testing (Phase 3)Active Not RecruitingNCT06462001
What this trial is testing

BCG + MMC: Adding Mitomycin C to BCG in High-risk, Non-muscle-invasive Bladder Cancer

Who this might be right for
Transitional Cell CarcinomaTransurethral Resection
Nottingham University Hospitals NHS Trust 500
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07189793
What this trial is testing

Toripalimab ± Sequential Intravesical Gemcitabine-Mitomycin C for BCG-Unresponsive/-Intolerant High-Risk NMIBC: Open-Label Randomized Phase 2 Study

Who this might be right for
Urinary Bladder NeoplasmsCarcinoma, Transitional CellCarcinoma in Situ of Bladder+1 more
First Affiliated Hospital of Wenzhou Medical University 106
Not applicableNot Yet RecruitingNCT07053748
What this trial is testing

Observational Clinical Study on High - Risk NMIBC Patients Choosing Trimodality Bladder - Sparing Therapy

Who this might be right for
High - Risk NMIBC
Peking University First Hospital 30
Testing effectiveness (Phase 2)Looking for participantsNCT06971614
What this trial is testing

T3011 in Patients With BCG-Unresponsive NMIBC or BCG-Exposed, Chemotherapy-Unresponsive NMIBC

Who this might be right for
Nonmuscle-invasive Bladder Cancer
ImmVira Pharma Co. Ltd 160
Early research (Phase 1)Study completedNCT02808143
What this trial is testing

Pembrolizumab and BCG Solution in Treating Patients With Recurrent Non-Muscle-Invasive Bladder Cancer

Who this might be right for
Recurrent Bladder CarcinomaStage 0a Bladder Urothelial CarcinomaStage 0is Bladder Urothelial Carcinoma+1 more
Northwestern University 9
Early research (Phase 1)Study completedNCT03053635
What this trial is testing

Intravesical Photodynamic Therapy (PDT) in BCG Refractory High-Risk Non-muscle Invasive Bladder Cancer (NMIBC) Patients

Who this might be right for
Non-Muscle Invasive Bladder Cancer (NMIBC) Refractory to BCG
Theralase® Technologies Inc. 6
Not applicableUnknownNCT05276167
What this trial is testing

Hyperthermic Intravesical Perfusion for Muscle-invasive Bladder Urothelial Carcinoma

Who this might be right for
High-Risk, Non-Muscle Invasive Bladder Urothelial CarcinomaPerfusion; ComplicationsIntraoperative Complications
Henan Cancer Hospital 40
Testing effectiveness (Phase 2)Looking for participantsNCT05943379
What this trial is testing

RC48-ADC in Combination With Gemcitabine in High Risk NMIBC Subjects

Who this might be right for
NMIBC
RemeGen Co., Ltd. 85
Not applicableEnded earlyNCT04412070
What this trial is testing

Assessement of the Concordance of Genomic Alterations Between Urine and Tissue in High-Risk NMIBC Patients

Who this might be right for
Bladder Cancer
Hopital Foch 20
Load More Results